Autochecked users, Comment administrators, Editors, Interface administrators, Reviewers, Suppressors, Administrators, Widget editors
3,458
edits
Changes
Repeat columns removed
Line 1:
Line 1:
−
+Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Details on clinical significance such as prognosis and other important information can be provided in the notes section. Please include references throughout the table. Do not delete the table.'')</span>
−{| class="wikitable sortable"
−|-
−!Driver Gene!!Fusion(s) and Common Partner Genes!!Molecular Pathogenesis!!Typical Chromosomal Alteration(s)
−!Prevalence -Common >20%, Recurrent 5-20% or Rare <5% (Disease)
−!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
−!Established Clinical Significance Per Guidelines - Yes or No (Source)
−!Clinical Relevance Details/Other Notes
−|-
−|<span class="blue-text">EXAMPLE:</span> ''ABL1''||<span class="blue-text">EXAMPLE:</span> ''BCR::ABL1''||<span class="blue-text">EXAMPLE:</span> The pathogenic derivative is the der(22) resulting in fusion of 5’ BCR and 3’ABL1.||<span class="blue-text">EXAMPLE:</span> t(9;22)(q34;q11.2)
−|<span class="blue-text">EXAMPLE:</span> Common (CML)
−|<span class="blue-text">EXAMPLE:</span> D, P, T
−|<span class="blue-text">EXAMPLE:</span> Yes (WHO, NCCN)
−|<span class="blue-text">EXAMPLE:</span>
−The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference). BCR::ABL1 is generally favorable in CML (add reference).
−|-
−|<span class="blue-text">EXAMPLE:</span> ''CIC''
−|<span class="blue-text">EXAMPLE:</span> ''CIC::DUX4''
−|<span class="blue-text">EXAMPLE:</span> Typically, the last exon of ''CIC'' is fused to ''DUX4''. The fusion breakpoint in ''CIC'' is usually intra-exonic and removes an inhibitory sequence, upregulating ''PEA3'' genes downstream of ''CIC'' including ''ETV1'', ''ETV4'', and ''ETV5''.
−|<span class="blue-text">EXAMPLE:</span> t(4;19)(q25;q13)
−|<span class="blue-text">EXAMPLE:</span> Common (CIC-rearranged sarcoma)
−|<span class="blue-text">EXAMPLE:</span> D
−|
−|<span class="blue-text">EXAMPLE:</span>
−''DUX4'' has many homologous genes; an alternate translocation in a minority of cases is t(10;19), but this is usually indistinguishable from t(4;19) by short-read sequencing (add references).
−|-
−|<span class="blue-text">EXAMPLE:</span> ''ALK''
−|<span class="blue-text">EXAMPLE:</span> ''ELM4::ALK''
−Other fusion partners include ''KIF5B, NPM1, STRN, TFG, TPM3, CLTC, KLC1''
−|<span class="blue-text">EXAMPLE:</span> Fusions result in constitutive activation of the ''ALK'' tyrosine kinase. The most common ''ALK'' fusion is ''EML4::ALK'', with breakpoints in intron 19 of ''ALK''. At the transcript level, a variable (5’) partner gene is fused to 3’ ''ALK'' at exon 20. Rarely, ''ALK'' fusions contain exon 19 due to breakpoints in intron 18.
−|<span class="blue-text">EXAMPLE:</span> N/A
−|<span class="blue-text">EXAMPLE:</span> Rare (Lung adenocarcinoma)
−|<span class="blue-text">EXAMPLE:</span> T
−|
−|<span class="blue-text">EXAMPLE:</span>
−Both balanced and unbalanced forms are observed by FISH (add references).
−|-
−|<span class="blue-text">EXAMPLE:</span> ''ABL1''
−|<span class="blue-text">EXAMPLE:</span> N/A
−|<span class="blue-text">EXAMPLE:</span> Intragenic deletion of exons 2–7 in ''EGFR'' removes the ligand-binding domain, resulting in a constitutively active tyrosine kinase with downstream activation of multiple oncogenic pathways.
−|<span class="blue-text">EXAMPLE:</span> N/A
−|<span class="blue-text">EXAMPLE:</span> Recurrent (IDH-wildtype Glioblastoma)
−|<span class="blue-text">EXAMPLE:</span> D, P, T
−|
−|
−|-
−|
−|
−|
−|
−|
−|
−|
−|
−|}
−Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene rearrangements. Details on clinical significance such as prognosis and other important information can be provided in the notes section. Can refer to CGC workgroup tables as linked on the homepage if applicable. Please include references throughout the table. Do not delete the table.'') </span>
−{| class="wikitable sortable"
−|-
−!Chr #!!'''Gain, Loss, Amp, LOH'''!!'''Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]'''!!'''Relevant Gene(s)'''
−!'''Diagnostic, Prognostic, and Therapeutic Significance - D, P, T'''
−!'''Established Clinical Significance Per Guidelines - Yes or No (Source)'''
−!'''Clinical Relevance Details/Other Notes'''
−|-
−|<span class="blue-text">EXAMPLE:</span>
−7
−|<span class="blue-text">EXAMPLE:</span> Loss
−|<span class="blue-text">EXAMPLE:</span>
−chr7
−|<span class="blue-text">EXAMPLE:</span>
−Unknown
−|<span class="blue-text">EXAMPLE:</span> D, P
−|<span class="blue-text">EXAMPLE:</span> No
−|<span class="blue-text">EXAMPLE:</span>
−Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference). Monosomy 7/7q deletion is associated with a poor prognosis in AML (add references).
−|-
−|<span class="blue-text">EXAMPLE:</span>
−8
−|<span class="blue-text">EXAMPLE:</span> Gain
−|<span class="blue-text">EXAMPLE:</span>
−chr8
−|<span class="blue-text">EXAMPLE:</span>
−Unknown
−|<span class="blue-text">EXAMPLE:</span> D, P
−|
−|<span class="blue-text">EXAMPLE:</span>
−Common recurrent secondary finding for t(8;21) (add references).
−|-
−|<span class="blue-text">EXAMPLE:</span>
−17
−|<span class="blue-text">EXAMPLE:</span> Amp
−|<span class="blue-text">EXAMPLE:</span>
−17q12; chr17:39,700,064-39,728,658 [hg38; 28.6 kb]
−|<span class="blue-text">EXAMPLE:</span>
−''ERBB2''
−|<span class="blue-text">EXAMPLE:</span> D, P, T
−|
−|<span class="blue-text">EXAMPLE:</span>
−Amplification of ''ERBB2'' is associated with HER2 overexpression in HER2 positive breast cancer (add references). Add criteria for how amplification is defined.
−|-
−|
−|
−|
−|
−|
−|
−|
−|}
−Put your text here and fill in the table <span style="color:#0070C0">(I''nstructions: Included in this category are alterations such as hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis; microsatellite instability; homologous recombination deficiency; mutational signature pattern; etc. Details on clinical significance such as prognosis and other important information can be provided in the notes section. Please include references throughout the table. Do not delete the table.'')</span>
−{| class="wikitable sortable"
−|-
−!Chromosomal Pattern
−!Molecular Pathogenesis
−!'''Prevalence -'''
−'''Common >20%, Recurrent 5-20% or Rare <5% (Disease)'''
−!'''Diagnostic, Prognostic, and Therapeutic Significance - D, P, T'''
−!'''Established Clinical Significance Per Guidelines - Yes or No (Source)'''
−!'''Clinical Relevance Details/Other Notes'''
−|-
−|<span class="blue-text">EXAMPLE:</span>
−Co-deletion of 1p and 18q
−|<span class="blue-text">EXAMPLE:</span> See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).
−|<span class="blue-text">EXAMPLE:</span> Common (Oligodendroglioma)
−|<span class="blue-text">EXAMPLE:</span> D, P
−|
−|
−|-
−|<span class="blue-text">EXAMPLE:</span>
−Microsatellite instability - hypermutated
−|
−|<span class="blue-text">EXAMPLE:</span> Common (Endometrial carcinoma)
−|<span class="blue-text">EXAMPLE:</span> P, T
−|
−|
−|-
−|
−|
−|
−|
−|
−|
−|}
−Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent or common as well either disease defining and/or clinically significant. If a gene has multiple mechanisms depending on the type or site of the alteration, add multiple entries in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity. Details on clinical significance such as prognosis and other important information such as concomitant and mutually exclusive mutations can be provided in the notes section. Please include references throughout the table. Do not delete the table.'') </span>
−{| class="wikitable sortable"
−|-
−!Gene!!'''Genetic Alteration'''!!'''Tumor Suppressor Gene, Oncogene, Other'''!!'''Prevalence -'''
−'''Common >20%, Recurrent 5-20% or Rare <5% (Disease)'''
−!'''Diagnostic, Prognostic, and Therapeutic Significance - D, P, T '''
−!'''Established Clinical Significance Per Guidelines - Yes or No (Source)'''
−!'''Clinical Relevance Details/Other Notes'''
−|-
−|<span class="blue-text">EXAMPLE:</span>''EGFR''
−<br />
−|<span class="blue-text">EXAMPLE:</span> Exon 18-21 activating mutations
−|<span class="blue-text">EXAMPLE:</span> Oncogene
−|<span class="blue-text">EXAMPLE:</span> Common (lung cancer)
−|<span class="blue-text">EXAMPLE:</span> T
−|<span class="blue-text">EXAMPLE:</span> Yes (NCCN)
−|<span class="blue-text">EXAMPLE:</span> Exons 18, 19, and 21 mutations are targetable for therapy. Exon 20 T790M variants cause resistance to first generation TKI therapy and are targetable by second and third generation TKIs (add references).
−|-
−|<span class="blue-text">EXAMPLE:</span> ''TP53''; Variable LOF mutations
|<span class="blue-text">EXAMPLE:</span> Variable LOF mutations
−|<span class="blue-text">EXAMPLE:</span> Tumor Supressor Gene
−|<span class="blue-text">EXAMPLE:</span> Common (breast cancer)
−|<span class="blue-text">EXAMPLE:</span> P
−|
−|<span class="blue-text">EXAMPLE:</span> >90% are somatic; rare germline alterations associated with Li-Fraumeni syndrome (add reference). Denotes a poor prognosis in breast cancer.
−|-
−|<span class="blue-text">EXAMPLE:</span> ''BRAF''; Activating mutations
−|<span class="blue-text">EXAMPLE:</span> Activating mutations
−|<span class="blue-text">EXAMPLE:</span> Oncogene
−|<span class="blue-text">EXAMPLE:</span> Common (melanoma)
−|<span class="blue-text">EXAMPLE:</span> T
−|
−|
−|-
−|
−|
−|
−|
−|
−|
−|
−|}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
−Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent or common as well either disease defining and/or clinically significant. If a gene has multiple mechanisms depending on the type or site of the alteration, add multiple entries in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity. Details on clinical significance such as prognosis and other important information such as concomitant and mutually exclusive mutations can be provided in the notes section. Please include references throughout the table. Do not delete the table.'') </span>
Put your text here
{{DISPLAYTITLE:Phyllodes tumour}}[[BRST5:Table_of_Contents|Breast Tumours (WHO Classification, 5th ed.)]]
+{{DISPLAYTITLE:Phyllodes tumour}}
+[[BRST5:Table_of_Contents|Breast Tumours (WHO Classification, 5th ed.)]]
{{Under Construction}}
{{Under Construction}}
Line 63:
Line 65:
==Gene Rearrangements==
==Gene Rearrangements==
−==Individual Region Genomic Gain/Loss/LOH==
==Individual Region Genomic Gain/Loss/LOH==
−<br />
<br />
{| class="wikitable sortable"
{| class="wikitable sortable"
Line 285:
Line 172:
==Characteristic Chromosomal or Other Global Mutational Patterns==
==Characteristic Chromosomal or Other Global Mutational Patterns==
−<br />
<br />
{| class="wikitable sortable"
{| class="wikitable sortable"
Line 343:
Line 193:
==Gene Mutations (SNV/INDEL)==
==Gene Mutations (SNV/INDEL)==
−<br />
<br />
−{| class="wikitable sortable"
{| class="wikitable sortable"
|-
|-
Line 502:
Line 305:
−==Genes and Main Pathways Involved==
==Genes and Main Pathways Involved==
Line 546:
Line 348:
<br /><references />
<br /><references />
<nowiki>*</nowiki>''Citation of this Page'': “Phyllodes tumour”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/BRST5:Phyllodes tumour</nowiki>.
<nowiki>*</nowiki>''Citation of this Page'': “Phyllodes tumour”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/BRST5:Phyllodes tumour</nowiki>.
−[[Category:BRST5]][[Category:DISEASE]][[Category:Diseases P]]
+[[Category:BRST5]]
+[[Category:DISEASE]]
+[[Category:Diseases P]]